In just 10 months at the head of Germany’s Fresenius SE, chief executive officer Stephan Sturm has now inked the healthcare provider’s two biggest-ever deals.
With the US$4.3 billion acquisition of Illinois-based generic drugmaker Akorn Inc, announced late on Monday, Fresenius will get a stronger foothold in the US, with access to a network of retail pharmacies and outpatient clinics as well as the hospitals where it has traditionally marketed its products.
Akorn is to complement Fresenius’s Kabi medicines unit, which specializes in intravenous drugs.
Fresenius, Europe’s biggest publicly traded healthcare provider, also made a smaller purchase on Monday to gain Merck KGaA’s portfolio of biosimilars, which are copycat versions of complex biotechnology drugs.
It agreed to pay Merck 170 million euros (US$185.05 million), plus licensing fees and as much as 500 million euros in milestones.
With the two transactions, Sturm is further expanding the global reach of the Bad Homburg-based group, bolstering the medicines unit that is key to profit growth — and making a long-term bet on biosimilars.
The CEO had already agreed to spend more than US$6 billion on the Spanish hospital group IDC Salud Holding SLU, known as Quironsalud, last year in the company’s largest acquisition.
The Akorn and biosimilar deals make even more sense together than individually, Sturm said on Monday.
“Akorn brings us additional US market access to small and mid-sized clinics and retail pharmacies, and that access will be important for our biosimilars,” he said.
Akorn’s biggest shareholder, John Kapoor, who owns a quarter of the stock, has agreed to support the deal, Fresenius said.
Integrating the businesses would save about US$100 million each year, the companies predicted.
The payoff for biosimilars might take longer.
Fresenius said it expects to invest as much as 1.4 billion euros in patient trials and other development costs for biosimilars before the unit breaks even in 2022.
The first sales are targeted for the end of 2019, with revenue expected to reach high triple-digit millions of euros by 2023, it said.
Fresenius agreed to single-digit percentage royalties for Merck KGaA — which is a German company unrelated to Merck & Co in the US — based on sales.
Merck KGaA is working on copies of complex biologic drugs for cancer and inflammatory diseases and had a treatment in late-stage tests for chronic plaque psoriasis that’s similar to AbbVie Inc’s Humira, one of the world’s best-selling medicines.
Fresenius expects the transaction to lift earnings per share from 2019 on and plans to raise both euro and US dollar-denominated debt to finance the deal.
The additional borrowings should remain “manageable,” analysts at Berenberg yesterday told clients in a note.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day